Arcus Biosciences, Inc.

Equities

RCUS

US03969F1093

Biotechnology & Medical Research

Market Closed - Nyse 04:00:02 2024-07-18 pm EDT 5-day change 1st Jan Change
14.73 USD -4.84% Intraday chart for Arcus Biosciences, Inc. -1.27% -22.88%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Arcus Biosciences Says Taiho Has Exercised Option for Exclusive License to Quemliclustat in Japan MT
Sector Update: Health Care Stocks Advance in Afternoon Trading MT
ITeos, Arcus Shares Drop After Genentech's Lung Cancer Study Misses Endpoints MT
Arcus Biosciences, Inc.(NYSE:RCUS) dropped from Russell 3000E Value Index CI
Arcus Biosciences, Inc.(NYSE:RCUS) dropped from Russell 3000 Value Index CI
Arcus Biosciences, Inc.(NYSE:RCUS) dropped from Russell 2500 Value Index CI
Arcus Biosciences, Inc.(NYSE:RCUS) dropped from Russell Small Cap Comp Value Index CI
Arcus Biosciences, Inc.(NYSE:RCUS) dropped from Russell 2000 Value Index CI
Truist Lowers Price Target on Arcus Biosciences to $44 From $50, Maintains Buy Rating MT
Transcript : Arcus Biosciences, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 10:00 AM
Arcus Completes Enrollment in Phase 3 Trial of Domvanalimab-Containing Regimen for Stomach Cancer MT
Arcus Biosciences, Inc. Completes Patient Enrollment in Phase 3 Trial Evaluating A Domvanalimab-Containing Regimen in First-Line Metastatic Upper GI Cancers CI
Citigroup Adjusts Arcus Biosciences Price Target to $38 From $36, Maintains Buy Rating MT
Gilead Sciences, Arcus Biosciences's Colorectal Cancer Combination Therapy Shows Promise MT
Gilead and Arcus Announces Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-Line Metastatic Colorectal Cancer CI
Gilead Sciences, Inc. and Arcus Biosciences, Inc. Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as A First-Line Treatment for Upper GI Cancers CI
Transcript : Arcus Biosciences, Inc. Presents at Bank of America Health Care Conference 2024, May-16-2024 10:00 AM
Transcript : Arcus Biosciences, Inc., Q1 2024 Earnings Call, May 08, 2024
Earnings Flash (RCUS) ARCUS BIOSCIENCES Posts Q1 Revenue $145M MT
Earnings Flash (RCUS) ARCUS BIOSCIENCES Posts Q1 Revenue $145M MT
Arcus Biosciences, Inc. Reports Impairment of Long-Lived Assets for the First Quarter Ended March 31, 2024 CI
Arcus Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Transcript : Arcus Biosciences, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 02:35 PM
Arcus Biosciences Insider Sold Shares Worth $1,177,967, According to a Recent SEC Filing MT
Arcus Biosciences Insider Sold Shares Worth $543,187, According to a Recent SEC Filing MT
Chart Arcus Biosciences, Inc.
More charts
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company involves in a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
14.73 USD
Average target price
33.89 USD
Spread / Average Target
+130.07%
Consensus
  1. Stock Market
  2. Equities
  3. RCUS Stock
  4. News Arcus Biosciences, Inc.
  5. Arcus Completes Enrollment in Phase 3 Trial of Domvanalimab-Containing Regimen for Stomach Cancer